• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IMRX

    Immuneering Corporation

    Subscribe to $IMRX
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Immuneering Corporation

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    3/30/2023$10.00Neutral
    Mizuho
    2/3/2023$12.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    See more ratings

    Immuneering Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:59:25 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R bought $2,499 worth of shares (700 units at $3.57), increasing direct ownership by 7% to 10,729 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:52:03 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Zeskind Benjamin J. bought $34,879 worth of shares (10,000 units at $3.49), increasing direct ownership by 0.43% to 2,312,852 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/3/25 9:12:08 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $34,788 worth of shares (9,500 units at $3.66), increasing direct ownership by 22% to 52,885 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/30/25 9:09:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $34,616 worth of shares (13,422 units at $2.58), increasing direct ownership by 4% to 359,318 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/25 9:01:43 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Brakewood Harold Eugene bought $4,804 worth of shares (1,900 units at $2.53), increasing direct ownership by 49% to 5,800 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/25 8:52:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Feinberg Peter bought $63,188 worth of shares (25,000 units at $2.53), increasing direct ownership by 22% to 136,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/23/25 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Zeskind Benjamin J. bought $50,144 worth of shares (21,000 units at $2.39), increasing direct ownership by 0.92% to 2,302,852 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/20/25 9:09:33 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $89,278 worth of shares (40,485 units at $2.21), increasing direct ownership by 1,396% to 43,385 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/18/25 9:11:22 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

    NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering's Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 2,843,987 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from t

    9/25/25 12:08:31 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

    NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the "Offering"). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A common stock equal to fifteen percent (15%) of the shares of Class A common stock and pre-funded warrants initially offered in the Offering. Immuneering also announced that Sanofi has entered into a sec

    9/24/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcita

    9/24/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

    - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. Th

    9/10/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Closing of $25 Million Private Placement

    CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately $25 million, before deducting fees and expenses. Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company's Class A common stock at a purchase price of $3.95 per share (or, for certain investors in lieu of Class A common stock, pre-funded warrants to purchase shares of Class A common stock), an

    8/26/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

    - Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial in patients with loc

    8/25/25 8:00:00 AM ET
    $IMRX
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces $25 Million Private Placement

    CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement for a private placement of securities to top-tier institutional and other accredited investors, that is expected to result in up front gross proceeds to the Company of approximately $25 million, before deducting fees and expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about August 26, 2025. "We are excited to announce updated Overall Survival (OS) and Progression-Free Su

    8/21/25 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

    - Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N = 34) - - Newly issued U.S. composition of matter patent for atebimetinib expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - Request for End of Phase 2 meeting has been submitted to the FDA; pivotal trial expected to initiate in 2026 - CAMBRIDGE, Mass., Aug. 13,

    8/13/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R was granted 11,815 shares, increasing direct ownership by 110% to 22,544 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/17/25 4:41:20 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Morales Mallory was granted 14,497 shares, increasing direct ownership by 114% to 27,233 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/17/25 4:35:58 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew was granted 14,880 shares, increasing direct ownership by 4% to 374,198 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/17/25 4:30:19 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hausman Diana bought $19,862 worth of shares (5,500 units at $3.61) (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:59:25 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R bought $2,499 worth of shares (700 units at $3.57), increasing direct ownership by 7% to 10,729 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/7/25 8:52:03 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Zeskind Benjamin J. bought $34,879 worth of shares (10,000 units at $3.49), increasing direct ownership by 0.43% to 2,312,852 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    7/3/25 9:12:08 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $34,788 worth of shares (9,500 units at $3.66), increasing direct ownership by 22% to 52,885 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/30/25 9:09:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $34,616 worth of shares (13,422 units at $2.58), increasing direct ownership by 4% to 359,318 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/25 9:01:43 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Brakewood Harold Eugene bought $4,804 worth of shares (1,900 units at $2.53), increasing direct ownership by 49% to 5,800 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    6/24/25 8:52:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Leadership Updates

    Live Leadership Updates

    View All

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

    5/7/24 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

    CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

    3/12/24 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

    - Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May

    5/4/23 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Harold E. Brakewood as Chief Business Officer

    CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E. Brakewood ("E.B.") as its Chief Business Officer. Mr. Brakewood, who has more than 25 years of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development, new product planning, and commercial strategy. "We are excited to have E.B. join Immuneering's senior leadership team as we continue to advance our oncology pipeli

    3/28/23 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

    Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter  Shares Promising Preclinical Data on Second Program IMM-6-415 at the 37th Annual Meeting of SITC, Demonstrating Preclinical Single Agent Activity in RAF and RAS Mutant Tumors and Enhancement of PD1 and CTLA4 Checkpoint Blockade Cash, Cash Equivalents and Marketable Securities of $117.2M is Expected to Provide Cash Runway into Q3 2024  CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company that aims to create medicines for all patients with

    11/10/22 9:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Leah R. Neufeld as Chief People Officer

    CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately. "Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people," stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. "Leah is a seasoned human resources leader with decades of experience in the life scie

    10/20/22 6:50:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Laurie Keating as Chair of Board of Directors

    BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu

    1/19/22 8:00:00 AM ET
    $IMGO
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

    CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors. This appointment brings Immuneering's Board to six members. "Diana has dedicated her career to creating new and better possibilities for cancer patients, as a Board certified oncologist with more than 20 years of clinical drug development

    1/18/22 6:50:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

    CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately. In this role, Dr. Steinhertz will focus on working with Immuneering's leadership team as it advances IMM-1-104 as a monotherapy into clinical trials in 2022 and working with potential future partners to advance combination approaches with IMM-1-104 in select patient

    1/3/22 6:50:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/15/24 6:10:57 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/10/24 12:58:49 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/5/24 12:21:51 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    3/27/24 1:12:56 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    2/14/24 4:57:08 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    2/14/24 10:03:04 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immuneering Corporation

    SC 13G - Immuneering Corp (0001790340) (Subject)

    1/26/24 4:23:44 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    1/16/24 4:37:18 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation SEC Filings

    View All

    SEC Form 424B5 filed by Immuneering Corporation

    424B5 - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:26:30 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:23:28 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Immuneering Corporation

    FWP - Immuneering Corp (0001790340) (Subject)

    9/25/25 6:01:41 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Immuneering Corporation

    FWP - Immuneering Corp (0001790340) (Subject)

    9/24/25 5:13:10 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Immuneering Corporation

    424B5 - Immuneering Corp (0001790340) (Filer)

    9/24/25 5:05:50 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    9/24/25 4:15:26 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Immuneering Corporation

    144 - Immuneering Corp (0001790340) (Subject)

    9/23/25 8:48:20 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Immuneering Corporation

    D - Immuneering Corp (0001790340) (Filer)

    9/9/25 4:46:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Immuneering Corporation

    EFFECT - Immuneering Corp (0001790340) (Filer)

    9/9/25 12:15:36 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Immuneering Corporation

    424B3 - Immuneering Corp (0001790340) (Filer)

    9/8/25 5:08:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immuneering Corporation downgraded by Morgan Stanley

    Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

    12/13/24 8:04:38 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on Immuneering Corporation with a new price target

    Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

    3/15/24 7:50:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation downgraded by TD Cowen

    TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

    3/15/24 7:19:50 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation downgraded by Jefferies with a new price target

    Jefferies downgraded Immuneering Corporation from Buy to Hold and set a new price target of $3.00 from $16.00 previously

    3/15/24 7:19:49 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on ImaRx Therapeutics with a new price target

    Needham initiated coverage of ImaRx Therapeutics with a rating of Buy and set a new price target of $20.00

    12/1/23 7:58:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on ImaRx Therapeutics with a new price target

    Oppenheimer resumed coverage of ImaRx Therapeutics with a rating of Outperform and set a new price target of $25.00

    6/26/23 7:25:06 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImaRx Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded ImaRx Therapeutics from Underweight to Equal-Weight and set a new price target of $14.00 from $5.00 previously

    4/19/23 7:39:12 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImaRx Therapeutics upgraded by Mizuho with a new price target

    Mizuho upgraded ImaRx Therapeutics from Neutral to Buy and set a new price target of $20.00 from $10.00 previously

    4/19/23 7:38:40 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on ImaRx Therapeutics with a new price target

    Mizuho initiated coverage of ImaRx Therapeutics with a rating of Neutral and set a new price target of $10.00

    3/30/23 7:36:14 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImaRx Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded ImaRx Therapeutics from Equal-Weight to Underweight and set a new price target of $5.00 from $12.00 previously

    2/3/23 7:32:55 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation Financials

    Live finance-specific insights

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcita

    9/24/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

    - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. Th

    9/10/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

    - 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable - - Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile - - Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 - - Company to host conference call at 8:00 a.m

    6/17/25 6:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

    CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8:00 am ET on June 17, 2025. The company is excited to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The conference call will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a clinical-stage oncology company outpacing cancer to help pati

    6/16/25 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

    - Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros

    1/7/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

    - In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res

    9/12/24 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

    - IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combin

    3/14/24 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

    Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predictedPharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected Study timeline accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024Investor call to be held today at 9.00 a.m. ET CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIR

    4/18/23 9:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

    CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will hold a virtual Investor Event concurrent with a data presentation on its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023. The virtual Investor Event will be held at 9:00 a.m. ET on April 18, 2023. To access the Investor Event by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to di

    4/5/23 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care